Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Mountain of sadness for some. Mountains of money for others...(like me for instance!)
ELTP Tanksolidation continues!!
Or not!
Bid is already below yesterday's close so to me it is telling me RED will be a reality by EOD.
Green now. LOL LOL LOL
This is some way to chew up posts.
They said no such thing.
It's a chart of the PPS. Why do you keep asking about revenues and losses? The PPS is UP. That is kind of what I look for in an investment. Sorry if that does not impress you. I am a very happy camper.
Umm, he just showed a chart of the PPS.
As an investor I find that quite meaningful (and comforting).
He is referring to this I believe:
http://www.crilifetree.com/media/abstracts/EuphoriaPoster0208.pdf
This article is of interest to investors in Elite, because Elite is developing abuse-deterrent formulations of opioids.
This article suggests that the FDA should take steps to aid in the speed of development of said formulations.
LOL
"Building on its own work to advance the science of abuse-deterrent formulations, the FDA should also require that prescription opioids meet basic deterrent standards and should facilitate the gradual reformulation of existing products to meet such standards."
Troy, that is quite a bold prediction. What is it predicated on? Or did you just pull that out of something?
Elite can move at Hakim Speed!
Trails? Elite is building trails now?
Wow, given my moniker that makes me very happy!!
Oh, but if you meant trials...who assured no trials would be necessary? That is quite a bold statement. Can you back up that ELITE stated that NO trials would be required?
Well, that was helpful.
Agreed. So do you think it's going to .20? If so, why?
Thanks!
Awesome isn't it?
And the Ask is above yesterdays closing.
Again, what is your point? You seem unhappy. Why so sad?
Here, let me save you some time.
http://ih.advfn.com/p.php?pid=historical&symbol=NB%5EELTP
So what is your point? Is anything I just said not true?
Has the stock NOT gone up from .068 to .377?
I'm ecstatic!
Wow, Couch!
That is some serious DD there!
Thanks!
"Only" .39? I can pay off my mortgage today if I wanted to!
Who is Barbara?
What makes you think Elite needs saving? They are doing quite well!
Nasrat world class? You bet! Stock price was .068 just 8 months ago!
Who else is using NE30D and NE40D in ART 2 bead formulations? Nobody.
Does Elite have this patented? Yes.
Does the Elite tech work? Yes.
Can anyone else copy it? No.
Pretty spectacular? Yes.
I think a doctor could/would still be inclined to prescribe ART as a matter of minimizing legal liability.
What exactly is also ran about Elites tech?
But what if they do?
At the current market cap and given their recent proven performance....
Exactly
Pfizer and Purdue have marketed no more successful ART drugs than Elite has yet Elite has multiple ART drugs in development ....the big differentiator is the respective market caps hence the investment opportunity that many have already realized and may very well realize many times over in the coming year.
Wow
Acura, Pfizer ...etc
No one has marketed an opioid with ART/ADT yet huh?
Nicely and with great humor said.
Yes, why not?
You never heard of wash trading? really?
Didn't see Pfizer or Purdue either, folks holding those stocks must be in an absolute panic! It was an article about Zohydro.
I for one thank Gman for a very interesting and relevant link.
Elite could very well develop an abuse resistant version of Zohydro.
Heck, they may have already developed it.
.00357 of the O/S has traded. And many of those shares were bought and sold more than once...
Maybe Elite should move to Ireland.
ELITE PHARMACEUTICALS ANNOUNCES RESULTS OF 2014 ANNUAL MEETING OF SHAREHOLDERS
NORTHVALE, N.J. – May 23, 2014 – Elite Pharmaceuticals, Inc. ("Elite" or the "Company") ("Elite”) (OTCBB: ELTP) today announced the voting results of matters considered during the Company’s annual meeting of shareholders held on May 21, 2014. Of the shares entitled to vote at this meeting, 89.18% shares were voted for this meeting.
Shareholders elected the six board of director nominees, approved the Articles of Incorporation to increase the number of shares of common stock the Company is authorized to issue, ratified the appointment of the Company’s independent accounting firm, approved a management advisory proposal on compensation of named executive offices, recommended that the Company seek advisory vote on executive compensation every three years and approved the Company’s 2014 Equity Incentive Plan.
"As steward of our Company, my primary focus is to achieve long-term company growth through prudent execution of strong and effective business strategies. With the support we have received from our shareholders, we are now in a position to continue with the execution of the business strategies we have in place,” said Nasrat Hakim, Elite’s President and CEO. "Following the results of the vote, I wish to thank each of our shareholders who participated in the very important process of voting of their shares and in their overwhelming support of the Company. I am grateful for the vote of confidence Elite’s management has received from our shareholders.”
Final voting results will be included in Form 8-K to be filed today.
About Elite Pharmaceuticals, Inc.
Elite Pharmaceuticals, Inc. develops oral sustained and controlled release products. Elite has seven commercial products currently being sold, eleven additional approved products pending manufacturing site transfer and two additional products under review pending approval by the FDA. Elite’s lead pipeline products include abuse resistant opioids utilizing the Company’s patented proprietary technology and include sustained release oral formulations of opioids for the treatment of chronic pain, which address two of the limitations of existing oral opioids: the provision of consistent relief of baseline pain levels and deterrence of potential abuse. Elite also provides contract manufacturing for Ascend Laboratories (a subsidiary of Alkem Laboratories Ltd.) and has partnered with Epic Pharma for the manufacturing and distribution of eleven approved products pending manufacturing site, with Hi-Tech Pharmacal to develop an intermediate for a generic product, and a Hong Kong based company to develop a branded product for the United States market and its territories. Elite operates a GMP and DEA registered facility for research, development, and manufacturing located in Northvale, NJ.
This news release contains "forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Including those related to the effects, if any, on future results, performance or other expectations that may have some correlation to the subject matter of this press release, readers are cautioned that such forward-looking statements involve risks and uncertainties including, without limitation, its ability to obtain FDA approval of the transfers of the ANDAs or the timing of such approval process, delays, uncertainties, inability to obtain necessary ingredients and other factors not under the control of Elite, which may cause actual results, performance or achievements of Elite to be materially different from the results, performance or other expectations that may be implied by these forward-looking statements. These risks and other factors, including, without limitation, the Company’s ability to obtain sufficient funding under the LPC Agreement or from other sources, the timing or results of pending and future clinical trials, regulatory reviews and approvals by the Food and Drug Administration and other regulatory authorities, intellectual property protections and defenses, and the Company’s ability to operate as a going concern, are discussed in Elite's filings with the Securities and Exchange Commission, including its reports on forms 10-K, 10-Q and 8-K. Elite undertakes no obligation to update any forward-looking statements.
Contact:
Elite Pharmaceuticals, Inc.
Dianne Will, Investor Relations, 518-398-6222
Dianne@elitepharma.com
How do you know that LPC or the MMs are employing any particular strategy? Do you have an insider at the SEC? LPC?
What? I can not comprehend a single thing in this post.
How is Elite "barely floating" and on what "hot air?"
What "weakened hype" are you talking about?
The market cap of this company has increased 25 fold. The PPS has increased 5 fold. All this has happened with considerable increase in the share count. Clearly the company has been wise, prudent and judicious in it decisions to increase the share count as the market cap and PPS have continued to rise a LOT in the face of said "dilution".
I'll take a doubling of the share count if the market cap quintuples or more!
Given that this has been in the works for a VERY long time I'd say any "negative" perception of the increase in AS has been well baked into the stock price.
Frankly now that the AS is done with management is free to pursue their plans. So the PPS may well increase.
I'll take 50% dilution to increase revenues 100 fold and them some anytime.
AJ
As apparently saying "Dude This" wasn't to iHub's standards...
Let me say this.
Thank you for the highly relevant and very much on topic set of links.
I have clicked on each and every one of them.
They demonstrate the high value and demand, both societal and governmental, of Elite's technology.
It was mentioned many times during and after the SHM meeting how the FDA was very supportive of any effort to bring ART drugs to market.
Mocha.
Got your PM but can not reply. I won't pay iHub!
Shoot me an email: hikeleader@gmail.com
Hike
Warren, I'd ask Dianne. She could probably mail you one.
Edit the address by changing https to http
That might fix it
OK, my 1st thoughts notes....
It was a great time!
Met MochaJet, Senderos, Couch, AJ, ELTP, JimmyJoe and others.
Spent time chatting with Nasrat, Dianne, Chris Dick, Jerry T., Ashok, Jeenarine (Jai), Carter, and Ram Potti.
Got my ELTP mug of course! Link to pic posted earlier.
All of the measures were voted in. It was a landslide.
Extensive Q&A session followed.
Some quotes/paraphrases from my scribbled notes:
"FDA is at the facility now" (regarding generic approvals)
"Going back to Rodman-Renshaw Conference Sept 9th and 10th"
"17 ART drugs"
"Little wave followed by tidal wave"
"Camargo meets regularly with FDA for guidance"
"Expecting filing of 1st ART in December"
"FDA has been encouraging"
"First ART NDA launch 8/2015" (hint of priority review based on FDA feedback)
New website in the works, Dianne is working on.
28 shareholders in attendance.
3800 shareholder letters went out according to Dianne.
Had a great post meeting review at Biddy O'Malley's with AJ and Couch. A most excellent discussion and really great guys.
What gave you that impression?
Hank
I imagine I saw you but we missed the chance to meet. I agree with your thoughts and observation about NH.